| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
|
Blood
|
2013
|
8.00
|
|
2
|
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
|
N Engl J Med
|
2007
|
7.91
|
|
3
|
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
|
Blood
|
2006
|
7.30
|
|
4
|
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
|
Blood
|
2006
|
4.40
|
|
5
|
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.
|
Clin Infect Dis
|
2004
|
3.10
|
|
6
|
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
|
Blood
|
2007
|
2.59
|
|
7
|
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
|
Lancet Infect Dis
|
2011
|
2.19
|
|
8
|
A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies.
|
Blood
|
2002
|
1.89
|
|
9
|
Early lymphocyte recovery at 28 d post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts.
|
Eur J Haematol
|
2014
|
1.39
|
|
10
|
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
|
J Clin Oncol
|
2009
|
1.35
|
|
11
|
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
|
Haematologica
|
2008
|
1.27
|
|
12
|
Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.
|
Br J Haematol
|
2009
|
1.22
|
|
13
|
Clinical and genetic analysis of unclassifiable inherited bone marrow failure syndromes.
|
Pediatrics
|
2008
|
1.19
|
|
14
|
A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation.
|
Transfusion
|
2007
|
1.17
|
|
15
|
Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
|
Clin Cancer Res
|
2009
|
1.16
|
|
16
|
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
1.08
|
|
17
|
Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older.
|
Biol Blood Marrow Transplant
|
2005
|
1.07
|
|
18
|
Myocyte enhancer factor 2C as a neurogenic and antiapoptotic transcription factor in murine embryonic stem cells.
|
J Neurosci
|
2008
|
1.06
|
|
19
|
Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance.
|
Biol Blood Marrow Transplant
|
2007
|
1.06
|
|
20
|
Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.
|
Leuk Res
|
2008
|
1.03
|
|
21
|
The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin.
|
Eur J Clin Pharmacol
|
2005
|
1.01
|
|
22
|
Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
|
Cancer
|
2008
|
0.99
|
|
23
|
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
|
Cancer
|
2015
|
0.98
|
|
24
|
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
|
Br J Haematol
|
2013
|
0.98
|
|
25
|
Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy.
|
Am J Hematol
|
2008
|
0.94
|
|
26
|
Outcomes of older patients (> or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy.
|
Br J Haematol
|
2008
|
0.93
|
|
27
|
Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population.
|
Biol Blood Marrow Transplant
|
2006
|
0.93
|
|
28
|
Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia.
|
Blood
|
2009
|
0.93
|
|
29
|
Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations.
|
J Mol Diagn
|
2007
|
0.93
|
|
30
|
No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
|
Cancer
|
2008
|
0.92
|
|
31
|
Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver.
|
Transfus Apher Sci
|
2002
|
0.91
|
|
32
|
A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia.
|
Blood
|
2011
|
0.90
|
|
33
|
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
|
Leuk Lymphoma
|
2004
|
0.90
|
|
34
|
Acute leukemia of donor origin arising after stem cell transplantation for acute promyelocytic leukemia.
|
Leuk Res
|
2004
|
0.89
|
|
35
|
Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms.
|
Blood
|
2013
|
0.89
|
|
36
|
Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.88
|
|
37
|
The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia.
|
Clin Cancer Res
|
2010
|
0.88
|
|
38
|
Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).
|
Leuk Res
|
2005
|
0.87
|
|
39
|
Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.
|
Cytokines Cell Mol Ther
|
2002
|
0.87
|
|
40
|
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol.
|
Br J Haematol
|
2012
|
0.85
|
|
41
|
Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
0.85
|
|
42
|
Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts.
|
Biol Blood Marrow Transplant
|
2007
|
0.84
|
|
43
|
RBC transfusion requirements after allogeneic marrow transplantation: impact of the before-transplant Hb level on transfusion and early survival.
|
Transfusion
|
2003
|
0.83
|
|
44
|
Clinico-biological features and prognostic significance of PML/RARalpha isoforms in adult patients with acute promyelocytic leukemia treated with all trans retinoic acid (ATRA) and chemotherapy.
|
Leuk Lymphoma
|
2004
|
0.83
|
|
45
|
A prospective study comparing the outcomes and health-related quality of life in adult patients with myeloid malignancies undergoing allogeneic transplantation using myeloablative or reduced-intensity conditioning.
|
Biol Blood Marrow Transplant
|
2011
|
0.83
|
|
46
|
Do allogeneic bone marrow transplant candidates match coping to controllability of pre-treatment stressors?
|
Psychol Health Med
|
2008
|
0.82
|
|
47
|
A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.82
|
|
48
|
Self-concept as a "BMT patient", illness intrusiveness, and engulfment in allogeneic bone marrow transplant recipients.
|
J Psychosom Res
|
2003
|
0.82
|
|
49
|
Multiple single-nucleotide polymorphism-based risk model for clinical outcomes after allogeneic stem-cell transplantation, especially for acute graft-versus-host disease.
|
Transplantation
|
2012
|
0.82
|
|
50
|
Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
|
Biol Blood Marrow Transplant
|
2008
|
0.81
|
|
51
|
BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
|
Br J Haematol
|
2012
|
0.81
|
|
52
|
Influence of one human leukocyte antigen mismatch on outcome of allogeneic bone marrow transplantation from related donors.
|
Hematology
|
2003
|
0.81
|
|
53
|
Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation.
|
Clin Transplant
|
2008
|
0.81
|
|
54
|
Clinical characteristics and outcome associated with pandemic (2009) H1N1 influenza infection in patients with hematologic malignancies: a retrospective cohort study.
|
Leuk Lymphoma
|
2012
|
0.80
|
|
55
|
Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia.
|
Cytokines Cell Mol Ther
|
2002
|
0.80
|
|
56
|
Application of CIBMTR risk score to NIH chronic GVHD at individual centers.
|
Blood
|
2014
|
0.80
|
|
57
|
Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
|
Clin Transplant
|
2013
|
0.80
|
|
58
|
Allogeneic peripheral blood stem cell transplantation significantly increases risk of chronic graft-versus-host disease of lung compared with bone marrow transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.78
|
|
59
|
Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia.
|
Am J Hematol
|
2007
|
0.78
|
|
60
|
Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter?
|
Am J Hematol
|
2010
|
0.78
|
|
61
|
Chlordiazepoxide for imatinib-induced muscular cramps.
|
Eur J Haematol
|
2006
|
0.78
|
|
62
|
Examining the safety and efficacy of a chemotherapy dosing method in Allogeneic Stem Cell Transplant patients of extreme body size.
|
J Oncol Pharm Pract
|
2009
|
0.77
|
|
63
|
Precursor lymphoblastic lymphoma reoccurring as a donor-derived neoplasm: a case report and review of the literature.
|
Arch Pathol Lab Med
|
2008
|
0.77
|
|
64
|
Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes.
|
Transfusion
|
2013
|
0.77
|
|
65
|
Therapeutic use of Aldara in chronic myeloid leukemia.
|
J Transl Med
|
2007
|
0.76
|
|
66
|
Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?
|
Leuk Lymphoma
|
2005
|
0.76
|
|
67
|
Complete remission of tumour with interleukin 2 therapy in a patient with non-Hodgkin's lymphoma post allogeneic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis.
|
Br J Haematol
|
2003
|
0.75
|
|
68
|
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.
|
Am J Hematol
|
2014
|
0.75
|
|
69
|
Lymphoproliferative Disorders in Patients with Chronic Myeloid Leukemia: A Single-Center Case Series.
|
Acta Haematol
|
2015
|
0.75
|
|
70
|
A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis.
|
Br J Haematol
|
2014
|
0.75
|
|
71
|
Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
72
|
Hyperthyroidism six years post-BMT for acute myeloblastic leukemia in a patient on long-term lithium therapy for bipolar affective disorder.
|
Leuk Lymphoma
|
2004
|
0.75
|
|
73
|
Erratum to "Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study" [Biol Blood Marrow Transplant 2016;22:1410-1415].
|
Biol Blood Marrow Transplant
|
2016
|
0.75
|
|
74
|
Presence of t(1;14)(p13;p11.2) in Philadelphia chromosome-negative cells in a patient with chronic myeloid leukemia.
|
Cancer Genet Cytogenet
|
2007
|
0.75
|
|
75
|
Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
|
Am J Hematol
|
2015
|
0.75
|
|
76
|
A case report and literature review of chronic graft-versus-host disease manifesting as polymyositis.
|
Int J Hematol
|
2015
|
0.75
|
|
77
|
Tale of two lymphomas: peripheral T-cell lymphoma after allogeneic stem-cell transplantation for marginal zone lymphoma.
|
J Clin Oncol
|
2012
|
0.75
|